// App-Quantinova.ai

5505 : Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.

Researchers

Presenter

  • Martee Leigh Hensley

Principal Investigators

  • Danielle Enserro

  • Helen Hatcher

  • P. B. Ottevanger

  • Anders Krarup-Hansen

  • Jean-Yves Blay

  • Cyril Fisher

  • Katherine M. Moxley

  • Shashikant B. Lele

  • Jayanthi Sivasothy Lea

  • Krishnansu Sujata Tewari

  • Premal H. Thaker

  • Oliver Zivanovic

  • David M. O'Malley

  • Katina Robison

  • David S. Miller

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • NRG Oncology, Buffalo, NY

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Radboud University Medical Center, Njmegen, Netherlands

  • University of Copenhagen, Copenhagen E, Denmark

  • Centre Leon Berard, Lyon, France

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Roswell Park Cancer Institute, Buffalo, NY

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • The Division of Gynecologic Oncology at the University of California, Irvine, Orange, CA

  • Washington University School of Medicine, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Ohio State University College of Medicine, Columbus, OH

  • Women and Infants Hospital in Rhode Island, Providence, RI

Locations

  • Netherlands

  • United Kingdom

  • United States

  • France

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Tumor protein p63

Drug/Treatment

  • Gemcitabine

  • Doxorubicin

  • Docetaxel

Outcome

  • Negative

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01533207

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved